The series of clinical wins for Novo Nordisk A/S's semaglutide shows no sign of abating after the once-weekly version of the drug, sold under the brand name Ozempic, came up trumps earlier than expected in a kidney disease trial.
Key Takeaways
- The Danish drugmaker has stopped the kidney outcomes trial of semaglutide called FLOW almost a year early
- The GLP-1 agonist showed signs of a clear benefit on renal impairment
- The data
The Danish drugmaker has stopped the kidney outcomes trial called FLOW almost a year earlier than scheduled which was evaluating the effect of Ozempic versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease
